-
Je něco špatně v tomto záznamu ?
Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives
M. Holecek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
ProQuest Central
od 1999-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1999-01-01 do Před 1 rokem
Psychology Database (ProQuest)
od 1999-01-01 do Před 1 rokem
- MeSH
- amoniak metabolismus MeSH
- enterocyty metabolismus MeSH
- fenylbutyráty škodlivé účinky farmakologie terapeutické užití MeSH
- glutamin metabolismus MeSH
- glutaminasa antagonisté a inhibitory MeSH
- hyperamonemie farmakoterapie etiologie metabolismus MeSH
- jaterní encefalopatie dietoterapie farmakoterapie metabolismus MeSH
- játra metabolismus MeSH
- kosterní svaly metabolismus MeSH
- kritický stav MeSH
- kyselina glutamová metabolismus farmakologie terapeutické užití MeSH
- kyseliny ketoglutarové škodlivé účinky farmakologie terapeutické užití MeSH
- ledviny metabolismus MeSH
- lékové interakce MeSH
- lidé MeSH
- mikrobiota MeSH
- mozek metabolismus MeSH
- orgánová specificita MeSH
- střeva mikrobiologie MeSH
- větvené aminokyseliny metabolismus terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15023634
- 003
- CZ-PrNML
- 005
- 20150729100847.0
- 007
- ta
- 008
- 150709s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11011-013-9428-9 $2 doi
- 035 __
- $a (PubMed)23996300
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Holecek, Milan $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Simkova 870, 500 38, Hradec Kralove, Czech Republic, holecek@lfhk.cuni.cz.
- 245 10
- $a Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy-therapeutic perspectives / $c M. Holecek,
- 520 9_
- $a There is substantial clinical and experimental evidence that ammonia is a major factor in the pathogenesis of hepatic encephalopathy. In the article is demonstrated that in hepatocellular dysfunction, ammonia detoxification to glutamine (GLN) in skeletal muscle, brain, and likely the lungs, is activated. In addition to ammonia detoxification, enhanced GLN production may exert beneficial effects on the immune system and gut barrier function. However, enhanced GLN synthesis may exert adverse effects in the brain (swelling of astrocytes or altered neurotransmission) and stimulate catabolism of branched-chain amino acids (BCAA; valine, leucine, and isoleucine) in skeletal muscle. Furthermore, the majority of GLN produced is released to the blood and catabolized in enterocytes and the kidneys to ammonia, which due to liver injury escapes detoxification to urea and appears in peripheral blood. As only one molecule of ammonia is detoxified in GLN synthesis whereas two molecules may appear in GLN breakdown, these events can be seen as a vicious cycle in which enhanced ammonia concentration activates synthesis of GLN leading to its subsequent catabolism and increase in ammonia levels in the blood. These alterations may explain why therapies targeted to intestinal bacteria have only a limited effect on ammonia levels in patients with liver failure and indicate the needs of new therapeutic strategies focused on GLN metabolism. It is demonstrated that each of the various treatment options targeting only one the of the ammonia-lowering mechanisms that affect GLN metabolism, such as enhancing GLN synthesis (BCAA), suppressing ammonia production from GLN breakdown (glutaminase inhibitors and alpha-ketoglutarate), and promoting GLN elimination (phenylbutyrate) exerts substantial adverse effects that can be avoided if their combination is tailored to the specific needs of each patient.
- 650 _2
- $a větvené aminokyseliny $x metabolismus $x terapeutické užití $7 D000597
- 650 _2
- $a amoniak $x metabolismus $7 D000641
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a enterocyty $x metabolismus $7 D020895
- 650 _2
- $a kyselina glutamová $x metabolismus $x farmakologie $x terapeutické užití $7 D018698
- 650 _2
- $a glutaminasa $x antagonisté a inhibitory $7 D005972
- 650 _2
- $a glutamin $x metabolismus $7 D005973
- 650 _2
- $a jaterní encefalopatie $x dietoterapie $x farmakoterapie $x metabolismus $7 D006501
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hyperamonemie $x farmakoterapie $x etiologie $x metabolismus $7 D022124
- 650 _2
- $a střeva $x mikrobiologie $7 D007422
- 650 _2
- $a kyseliny ketoglutarové $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D007656
- 650 _2
- $a ledviny $x metabolismus $7 D007668
- 650 _2
- $a játra $x metabolismus $7 D008099
- 650 _2
- $a mikrobiota $7 D064307
- 650 _2
- $a kosterní svaly $x metabolismus $7 D018482
- 650 _2
- $a orgánová specificita $7 D009928
- 650 _2
- $a fenylbutyráty $x škodlivé účinky $x farmakologie $x terapeutické užití $7 D010654
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00007770 $t Metabolic brain disease $x 1573-7365 $g Roč. 29, č. 1 (2014), s. 9-17
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23996300 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150709 $b ABA008
- 991 __
- $a 20150729100933 $b ABA008
- 999 __
- $a ok $b bmc $g 1083971 $s 906627
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 29 $c 1 $d 9-17 $i 1573-7365 $m Metabolic brain disease $n Metab Brain Dis $x MED00007770
- LZP __
- $a Pubmed-20150709